Pulmatrix Announces Presentation of Clinical Data Demonstrating iCALM Inhaled Therapeutic Reduced Airway Inflammation

Pulmatrix, a biotechnology company developing breakthrough therapies for respiratory diseases, today announced the results of a clinical study showing that an iCALM™ attenuated allergen-induced bronchitis in susceptible asthmatic patients.

More expert answers to viewers' whooping cough questions

During KING 5's May 9 special report on the whooping cough epidemic in Washington state, Dr. John Dunn from Group Health Cooperative answered viewers' question in an online chat . Dr. Dunn agreed to get answers to the many questions that came in but which he didn't have time to answer. The first group of questions below were answered by his Group Health colleagues -- Drs. David Grossman, Rob ...